Clinical Trial Update: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002 [Phase 3]

View source ↗

Summary

Phase 3 trial update on fulranumab monotherapy for osteoarthritis of the hip or knee has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• Fulranumab (fulranumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Osteoarthritis, Pain | Phase 3 | Status: COMPLETED